for having a "surveillance group [that] had more prior interventions than the control group." Yet in their own study, it appears that the entry percutaneous transluminal angioplasty (PTA) rate in the control group was 2.5 times higher than the flow group (Table 1, 
row 2).
The authors in [1] also criticize others [3] for having a "group [that] had a high thrombosis rate because of multiple thromboses in a small number of grafts." Yet the authors admit to this very shortcoming for their flow group, and explain that its high thrombosis rate "is misleading in that it was caused by multiple thromboses in three grafts." The poor comparability between their groups is even more pronounced when assessing entry graft age (Ram et al [1] , Table 2 ) where removing not three, but one graft from the control group makes it 9.6 months younger (P = 0.043) than the flow group! These disparities suggest a lack of uniformity among the three groups on the very issues being studied: PTA rate, thrombotic events (Table 1 , Row 1), and graft survival (age).
The lack of group uniformity for these crucial parameters is a consequence of the small number of patients inadequate for the high values of variation coefficient ratio of standard deviation to mean value (S/M) ( Table 1 , rows 3 and 4). To achieve credible data, Bland [4] suggests that authors should choose the number of patients based Table 2 and Figure 4 of Ram et al study [1] Table 2  3 Entry graft age days S/M 1.6 1.5 1. 2 4 Entry no. of PTA S/M 1.6 1.4 1.5
S/M, ratio of standard deviation to mean value. a Not included are rethrombosis events that occurred before Qa could be measured.
b Entry thrombosis rates, rates of preemptive PTA (the crucial parameters of this study), and methodology of calculations were not presented by authors in Table 2 nor in Methods. The author (W.D.P.) declined to clarify. We estimated PTA rate/patient by dividing entry PTA events by entry graft age days.
on the value of variation coefficient. This study would need at least 140 patients in each group to credibly identify differences of 30% (95th percent CI) [4] . At 32 to 35 patients per group, observed variations between groups must differ by a factor of more then 2.5 to have statistical credibility.
The fact that data of just one to three grafts reverses major statistical outcomes of a 2.3-year study gives evidence to inadequate group size in relation to the study purpose. This compromises the authors' clinical conclusions.
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